Management of metastatic esophagogastric junction adenocarcinoma

Toihata, Tasuku; Imamura, Yu; Watanabe, Masayuki; Baba, Hideo

doi:10.20517/2394-4722.2017.82

Cited by 2 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of GEJC has been increasing over several decades, doubling in the United States from 16% in 1973 to 32% in 2013 [ 2 , 3 ]. GEJC is often diagnosed at a relatively late stage when the disease has become unresectable, and patients with advanced/metastatic GEJC generally require multiple lines of therapy, as recurrence is common [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study

et al. 2021

View full text Add to dashboard Cite

Background Patients with advanced gastroesophageal junction cancer (GEJC) have poor survival outcomes, and GEJC-specific data from trials evaluating agents in gastric cancers (GCs) as a whole are lacking. Trifluridine/tipiracil (FTD/TPI) was approved for previously treated metastatic GC or GEJC (mGC/mGEJC) based on results of the phase 3 TAGS trial. Subgroup analyses by primary tumor type (GC or GEJC) in TAGS are reported here. Methods Pa tients with mGC/mGEJC treated with ≥ 2 prior chemotherapy regimens were randomized (2:1) to receive FTD/TPI or placebo, plus best supportive care. A pre-planned sub-analysis was performed to evaluate efficacy and safety outcomes by primary tumor type (GEJC or GC). Results Of 507 randomized patients, 145 (29%) had GEJC and 360 (71%) had GC as the primary disease site. Baseline characteristics were generally similar between the GEJC and GC subgroups, except that more patients in the GEJC subgroup had received ≥ 3 prior regimens (72 vs. 59% in the GC subgroup). Survival benefit with FTD/TPI was observed in both subgroups. The overall survival hazard ratio for FTD/TPI vs placebo was 0.75 (95% CI 0.50–1.11) and 0.67 (95% CI 0.52–0.87) in the GEJC and GC subgroups, respectively. Grade ≥ 3 adverse events of any cause were reported in 75 (77%) and 192 (81%) FTD/TPI-treated patients in the GEJC and GC subgroups, respectively. No new safety concerns were noted with FTD/TPI. Conclusion As in patients with GC, FTD/TPI showed an efficacy benefit in patients with GEJC in the TAGS trial, along with demonstrating a manageable safety profile.

show abstract

Section: Introductionmentioning

confidence: 99%

Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Although treatment for EGJ adenocarcinoma has been developed as a type of gastric cancer, recent comprehensive molecular analysis revealed differences in molecular mechanisms between EGJ and gastric adenocarcinomas. Toihata et al [8] reviewed recent evidence of treatment for advanced EGJ adenocarcinoma.…”

mentioning

confidence: 99%

Management of metastatic esophagogastric junction adenocarcinoma

Cited by 2 publications

References 41 publications

Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study

Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study

Introduction to the special issue on reviews of gastric cancer metastasis and treatment

Contact Info

Product

Resources

About